Adaptimmune Therapeutics plc - American Depositary Shares (ADAP)
How ADAP actually reacts to news — the realized, point-in-time move the market made, measured across 161 labeled events over the last three years with zero look-ahead.
ADAP’s median reaction, across the day.
Half of all Adaptimmune Therapeutics plc - American Depositary Shares news events land between -4.40% and +0.19% at 30 minutes.
Reaction stats as of 2026-08-13. Reaction = percent move vs. the price at the news timestamp.
Email me when ADAP moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ADAP’s baseline. Nothing else.
Get “How ADAP reacts to news” as a PDF.
A free one-page summary: ADAP’s median reaction to news and the full breakdown by event type — the numbers on this page, in one page.
Recent ADAP events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 25 Adaptimmune Therapeutics | SEC filing · Form 25 | SEC EDGAR | — | — | |
| Form POS AM Adaptimmune Therapeutics | SEC filing · Form POS | SEC EDGAR | — | — | |
| Form S-8 POS Adaptimmune Therapeutics | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Form 8-K Adaptimmune Therapeutics For: Oct 15 | SEC filing · Form 8-K | SEC EDGAR | -1.54% | -9.23% | |
| Form 8-K Adaptimmune Therapeutics For: Sep 22 | SEC filing · Form 8-K | SEC EDGAR | +3.56% | -11.05% | |
| Form 8-K Adaptimmune Therapeutics For: Sep 11 | SEC filing · Form 8-K | SEC EDGAR | -3.69% | +2.46% | |
| Form 8-K Adaptimmune Therapeutics For: Sep 06 | SEC filing · Form 8-K | SEC EDGAR | -0.23% | +10.56% | |
| Form 8-K Adaptimmune Therapeutics For: Aug 29 | SEC filing · Form 8-K | SEC EDGAR | -1.00% | -3.67% | |
| Form 8-K Adaptimmune Therapeutics For: Aug 15 | SEC filing · Form 8-K | SEC EDGAR | -4.33% | -20.27% | |
| Form 8-K Adaptimmune Therapeutics For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | -1.96% | -16.67% | |
| Form 10-Q Adaptimmune Therapeutics For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +0.77% | |
| Form 8-K Adaptimmune Therapeutics For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.77% | |
| Form 8-K Adaptimmune Therapeutics For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | -2.41% | -6.63% | |
| US WorldMeds Completes Acquisition of Adaptimmune's Cell-Therapy Portfolio; Ensures Continued Patient Access to Tecelra and Advances Development of lete-cel | Press release | PR Newswire | -2.18% | -13.54% | |
| Form 8-K Adaptimmune Therapeutics For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | -6.95% | -10.43% | |
| Form 8-K Adaptimmune Therapeutics For: Jul 27 | SEC filing · Form 8-K | SEC EDGAR | -6.67% | -33.33% | |
| Form 8-K Adaptimmune Therapeutics For: Jul 16 | SEC filing · Form 8-K | SEC EDGAR | +2.59% | +3.52% | |
| Form 8-K Adaptimmune Therapeutics For: May 29 | SEC filing · Form 8-K | SEC EDGAR | -1.60% | +3.72% | |
| Form 10-Q Adaptimmune Therapeutics For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.68% | +8.89% | |
| Form 8-K Adaptimmune Therapeutics For: May 13 | SEC filing · Form 8-K | SEC EDGAR | -7.05% | -17.68% | |
| Form 8-K Adaptimmune Therapeutics For: May 01 | SEC filing · Form 8-K | SEC EDGAR | +0.04% | +3.70% | |
| Form ARS Adaptimmune Therapeutics For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +3.70% | +2.63% | |
| Form DEF 14A Adaptimmune Therapeutics For: May 29 | SEC filing · Form DEF | SEC EDGAR | -2.61% | -6.58% | |
| Form S-3 Adaptimmune Therapeutics | SEC filing · Form S-3 | SEC EDGAR | +0.64% | -2.46% | |
| Form PRE 14A Adaptimmune Therapeutics For: May 29 | SEC filing · Form PRE | SEC EDGAR | -0.42% | +3.96% | |
| Form 8-K Adaptimmune Therapeutics For: Apr 14 | SEC filing · Form 8-K | SEC EDGAR | -0.42% | +3.96% | |
| Form 10-K Adaptimmune Therapeutics For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.05% | -11.35% | |
| Form 8-K Adaptimmune Therapeutics For: Mar 24 | SEC filing · Form 8-K | SEC EDGAR | +1.05% | -11.35% | |
| Form 8-K Adaptimmune Therapeutics For: Mar 20 | SEC filing · Form 8-K | SEC EDGAR | -16.28% | -34.88% | |
| Form 8-K Adaptimmune Therapeutics For: Dec 18 | SEC filing · Form 8-K | SEC EDGAR | -0.75% | +0.00% | |
| Dr Crystal Mackall Confirmed to Keynote Immuno-Oncology 360º 2025 | Press release | PR Web | -0.83% | +5.22% | |
| Form 10-Q Adaptimmune Therapeutics For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -8.03% | -27.01% | |
| Form 8-K Adaptimmune Therapeutics For: Nov 13 | SEC filing · Form 8-K | SEC EDGAR | +0.81% | -6.02% | |
| Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market Evolution - Technavio | Press release | PR Newswire | -0.63% | -3.32% | |
| Form 8-K Adaptimmune Therapeutics For: Nov 01 | SEC filing · Form 8-K | SEC EDGAR | +0.61% | +3.44% | |
| Immuno-Oncology 360º Announces 2025 Keynotes and Featured Speakers for the 11th Annual Meeting in Boston | Press release | PR Web | +0.63% | -2.45% | |
| ReCode Announces Two Key Additions to Scientific Advisory Board | Press release | Business Wire | +0.63% | -2.45% | |
| Form 8-K Adaptimmune Therapeutics For: Sep 23 | SEC filing · Form 8-K | SEC EDGAR | +1.57% | +2.21% | |
| Unlock the Full Potential of Cell and Gene Therapies: The 2024 GenScript Biotech Global Forum Heads to London | Press release | PR Newswire | +0.79% | +0.00% | |
| Form 10-Q Adaptimmune Therapeutics For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +4.81% | +4.81% | |
| Form 8-K Adaptimmune Therapeutics For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +4.81% | +4.81% | |
| Sarcoma Therapeutics Market size is set to grow by USD 1.11 billion from 2024-2028, Patient assistance programs boost the market, Technavio | Press release | PR Newswire | +0.00% | +0.00% | |
| American Society for Transplantation and Cellular Therapy Applauds FDA Approval of TECELRA(R) for Synovial Sarcoma Treatment | Press release | Accesswire | -1.92% | -5.77% | |
| Form 8-K Adaptimmune Therapeutics For: Aug 01 | SEC filing · Form 8-K | SEC EDGAR | -8.33% | -11.36% | |
| Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor | Press release | Business Wire | -8.33% | -11.36% | |
| Form 8-K Adaptimmune Therapeutics For: Jul 16 | SEC filing · Form 8-K | SEC EDGAR | +1.01% | +1.61% | |
| Form 8-K Adaptimmune Therapeutics For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | +1.91% | -0.95% | |
| Form 8-K Adaptimmune Therapeutics For: May 30 | SEC filing · Form 8-K | SEC EDGAR | -3.02% | -2.59% | |
| Form 10-Q Adaptimmune Therapeutics For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -5.22% | -10.45% | |
| Form 8-K Adaptimmune Therapeutics For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +2.70% | +4.20% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ADAP section they belong to.
More of the dataset.
ADAP earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Adaptimmune Therapeutics plc - American Depositary Shares's median reaction calculated?
Every labeled ADAP news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 161 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 28% of ADAP's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-08-13.
Does ADAP's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.